This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Tyagi, S.C., Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem, 1997. 168: p. 1–12.
Loechel, F., et al., Human ADAM 12 (meltrin alpha) is an active metalloprotease. J Biol Chem, 1998. 273: p. 16993–7.
Hayden, M.R. and S.C. Tyagi, Arteriogenesis: Angiogenesis within Unstable AtheroscleroticPlaque— Interactions with Extracellular Matrix. Curr Interv Cardiol Rep, 2000. 2: p. 218–227.
Tyagi, S., Dynamic role of extracellular matrix metalloproteinases in heart failure. Cardiovasc Pathol, 1998. 7: p. 153–159.
Brew, K., D. Dinakarpandian, and H. Nagase, Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta, 2000. 1477: p. 267–83.
Nagase, H. and Woessner, J.F., Matrix metalloproteinase. J Biol Chem, 1999. 274: p. 21491–21494.
Mujumdar, V.S., G.M. Aru, and S.C. Tyagi, Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem, 2001. 82: p. 491–500.
Miller, A., et al., Reversal of endocardial endothelial dysfunction by folic acid in homocysteinemic hypertensive rats. Am J Hypertens, 2002. 15: p. 157–63.
Michel, J.B., et al., Morphometric analysis of collagen network and plasma perfused capillary bed in the myocardium of rats during evolution of cardiac hypertrophy. Basic Res Cardiol, 1986. 81: p. 142–54.
Amann, K., et al., Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol, 1998. 9: p. 1018–22.
Miller, A., et al., Hyperhomocysteinemia induces multiorgan damage. Heart & Vessels, 2000. 15: p. 135–143.
Patel, R., et al., Simavastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation, 2001. 104: p. 317–324.
Capasso, J.M., T.F. Robinson, and P. Anversa, Alterations in collagen cross-linking impair myocardial contractility in the mouse heart. Circ Res, 1989. 65: p. 1657–64.
Matsubara, L.S., et al., Alterations in myocardial collagen content affect rat papillary muscle function. Am J Physiol, 2000. 279: p. H1534–9.
Aimes, R.T. and J.P. Quigley, Matrix metalloproteinase-2 is an interstitial collagenase. Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4-and 1/4-length fragments. J Biol Chem, 1995. 270: p. 5872–6.
Senior, R.M., et al., Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem, 1991. 266: p. 7870–5.
Rucklidge, G.J., et al., Turnover rates of different collagen types measured by isotope ratio mass spectrometry. Biochim Biophys Acta, 1992. 1156: p. 57–61.
Moses,.MA. and R. Langer, A metalloproteinase inhibitor as an inhibitor of neovascularization. J Cell Biochem, 1991. 47: p. 230–5.
Hayakawa, T., et al., Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett, 1992. 298: p. 29–32.
Tyagi, S.C., et al., Induction of tissue inhibitor of metalloproteinase and its mitogenic response to endothelial cells in human atherosclerotic and restenotic lesions. Can J Cardiol, 1996. 12: p. 353–62.
Nemeth, J.A. and C.L. Goolsby, TIMP-2, a growth-stimulatory protein from SV40-transformed human fibroblasts. Exp Cell Res, 1993. 207: p. 376–82.
Baker, A.H., et al., Divergent effects of tissue inhibitor of metalloproteinase-1,-2, or-3 overexpression on rat vascular smooth muscle cell invasion, proliferation, and death in vitro. TIMP-3 promotes apoptosis. J Clin Invest, 1998. 101: p. 1478–87.
Tummalapalli, C.M., B.J. Heath, and S.C. Tyagi, Tissue inhibitor of metalloproteinase-4 instigates apoptosis in transformed cardiac fibroblasts. J Cell Biochem, 2001. 80: p. 512–21.
Tyagi, S.C., A. Ratajska, and K.T. Weber, Myocardial matrix metalloproteinase(s): localization and activation. Mol Cell Biochem, 1993. 126: p. 49–59.
Radomski, A., et al., The role of nitric oxide and metalloproteinases in the pathogenesis of hyperoxia-induced lung injury in newborn rats. Br J Pharmacol, 1998. 125: p. 1455–62.
Tyagi, S.C., S. Kumar, and S. Borders, Reduction-oxidation (redox) state regulation of extracellular matrix metalloproteinases and tissue inhibitors in cardiac normal and transformed fibroblast cells. J Cell Biochem, 1996. 61: p. 139–51.
Frears, E.R., et al., Inactivation of tissue inhibitor of metalloproteinase-1 by peroxynitrite. FEBS Lett, 1996. 381: p. 21–4.
Stricklin, G.P. and J.R. Hoidal, Oxidant-mediated inactivation of TIMP. Matrix Suppl, 1992. 1: p. 325.
Shabani, F., J. McNeil, and L. Tippett, The oxidative inactivation of tissue inhibitor of metalloproteinase-1 (TIMP-1) by hypochlorous acid (HOCI) is suppressed by antirheumatic drugs. Free Radic Res, 1998. 28: p. 115–23.
Rohde, L.E., et al., Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation, 1999. 99: p. 3063–70.
Spinale, F.G., et al., Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function. Circ Res, 1999. 85: p. 364–76.
Hoppeler, H. and S. Kayar, Capillary and oxidative capacity of muscles. News in physiol Sci, 1988. 3: p. 113–116.
Cox, M.J., et al., Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol, 2002. 282: p. H1 197–205.
Pinsky, D.J., et al., Mechanical transduction of nitric oxide synthesis in the beating heart. Circ Res, 1997. 81: p. 372–9.
Babior, B.M., NADPH oxidase: an update. Blood, 1999. 93: p. 1464–76.
Roos, D., et al., Protection of human neutrophils by endogenous catalase: studies with cells from catalase-deficient individuals. J Clin Invest, 1980. 65: p. 1515–22.
Laycock, S.K., et al., Effects of chronic norepinephrine administration on cardiac function in rats. J Cardiovasc Pharmacol, 1995. 26: p. 584–9.
Givertz, M.M. and W.S. Colucci, New targets for heart-failure therapy: endothelin, inflammatory cytokines, and oxidative stress. Lancet, 1998. 352: p. SI34–8.
Chen, C.Y., Y.L. Huang, and T.H. Lin, Association between oxidative stress and cytokine production in nickel-treated rats. Arch Biochem Biophys, 1998. 356: p. 127–32.
Tyagi, S., M. Hayden, and J. Hall, Role of angiotensin in angiogenesis and cardiac fibrosis in heart failure, Angiotensin II Receptor Blockade: Physiological and clinical implications. Prog Exp Cardiol, 1998. 2: p. 537–549.
Varin, R., et al., Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation, 2000. 102: p. 351–6.
Li, P., et al., Angiotensin-(l–7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension, 1997. 29: p. 394–400.
Zhang, H., et al., Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res, 1999. 44: p. 215–22.
Cox, M.J., et al., Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer. Circulation, 2004. 109: p. 2123–2128.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science + Business Media, Inc.
About this chapter
Cite this chapter
Tyagi, S.C. (2005). Therapeutic Potential of TIMPs in Heart Failure. In: Villarreal, F.J. (eds) Interstitial Fibrosis in Heart Failure. Developments in Cardiovascular Medicine, vol 253. Springer, New York, NY. https://doi.org/10.1007/0-387-22825-X_18
Download citation
DOI: https://doi.org/10.1007/0-387-22825-X_18
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-22824-2
Online ISBN: 978-0-387-22825-9
eBook Packages: MedicineMedicine (R0)